Sonidegib

Introduction: What is Sonidegib?

Sonidegib is a medication primarily used in the treatment of certain types of skin cancer, specifically basal cell carcinoma (BCC). It belongs to a class of drugs known as hedgehog pathway inhibitors, which play a crucial role in regulating cell growth and development. By inhibiting this pathway, Sonidegib helps to slow down or stop the growth of cancer cells, making it an important option for patients with locally advanced basal cell carcinoma (laBCC) who have not responded to other treatments.

Uses of Sonidegib

Sonidegib is approved for the treatment of unresectable locally advanced basal cell carcinoma in adults. It is particularly indicated for patients who are not candidates for surgery or radiation therapy. The drug is effective in managing BCC that has recurred after surgery or has spread to other areas of the body. Its use is essential in providing an alternative treatment option for patients with limited choices.

How Does It Work?

Sonidegib works by blocking the hedgehog signaling pathway, which is crucial for the growth and survival of certain cancer cells. In normal cells, this pathway helps regulate cell division and differentiation. However, in cancer cells, it can become overactive, leading to uncontrolled growth. By inhibiting this pathway, Sonidegib effectively reduces the proliferation of cancer cells, thereby slowing down tumor growth and progression.

Dosage and Administration

The standard dosage of Sonidegib for adults is typically 200 mg taken orally once a day. It is available in tablet form and should be taken at the same time each day to maintain consistent levels in the bloodstream. Patients are advised to swallow the tablet whole with a glass of water and not to crush or chew it. No pediatric dosing recommendations exist; use is off-label and not recommended due to lack of data on pharmacokinetics, efficacy, or long-term risks in children/adolescents.

Side Effects of Sonidegib

Like all medications, Sonidegib can cause side effects.

Common side effects include:

• Muscle spasm
• Fatigue
• Nausea
• Diarrhea
• Loss of appetite
• Weight loss
• Alopecia
• Dysgeusia (Taste Disturbance)

Serious side effects may include:

• Liver problems (hepatic impairment or elevated transaminases)
• Severe skin reactions
• Heart rhythm changes
• Eye problems (such as vision changes)
• QT interval prolongation
• Rhabdomyolysis

Patients should report any unusual symptoms to their healthcare provider promptly.

Drug Interactions

Sonidegib may interact with several medications, which can affect how it works or increases the risk of side effects. Major drug interactions include:

• Strong CYP3A inhibitors (e.g., ketoconazole, ritonavir)
• Strong CYP3A inducers (e.g., rifampin, carbamazepine)
• Moderate CYP3A inhibitors/inducers (e.g., fluconazole, efavirenz)
• Substrates of BCRP transporters (e.g., rosuvastatin ? dose adjustment needed)
• Other medications that affect liver enzymes

Sonidegib may interact with several medications, which can affect how it works or may increase Sonidegib exposure or decrease efficacy. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Benefits of Sonidegib

The clinical advantages of using Sonidegib include:

• Targeted therapy: It specifically targets the hedgehog pathway, which is often overactive in BCC.
• Oral administration: The convenience of taking a pill daily rather than undergoing injections or infusions.
• Efficacy in advanced cases: It provides an effective treatment option for patients with advanced BCC who have limited alternatives.

Contraindications of Sonidegib

Certain individuals should avoid using Sonidegib, including:

• Pregnant women: It is Pregnancy Category X (absolute contraindication) and may cause harm to the developing fetus. Female patients of reproductive potential must enroll in the required REMS program and use effective contraception during treatment and for 20 months after the last dose.
• Individuals with severe liver disease: The drug is metabolized in the liver, and impaired function can lead to increased side effects.
• Patients with a known hypersensitivity to Sonidegib or any of its components.

Precautions and Warnings

Before starting Sonidegib, patients should undergo a thorough evaluation, including liver function tests (LFTs before initiation, every 3 weeks for 3 months, then monthly). Monitor CK levels for muscle symptoms. It is essential to monitor any signs of liver damage during treatment. Patients should be advised to avoid pregnancy during treatment and for a period after stopping the medication due to potential risks to the fetus (females: contraception during and 20 months after; males: 8 months after). Avoid strong CYP3A inhibitors/inducers; dose adjustments required.

FAQs

• What is Sonidegib used for? Sonidegib is used to treat locally advanced basal cell carcinoma in adults who cannot undergo surgery or radiation.
• How should I take Sonidegib? Take Sonidegib orally, once daily, at the same time each day, swallowing the tablet with water.
• What are the common side effects? Common side effects include muscle spasm, fatigue, nausea, and diarrhea.
• Can I take Sonidegib if I am pregnant? No, Sonidegib is contraindicated in pregnancy due to potential harm to the fetus.
• How does Sonidegib work? It inhibits the hedgehog signaling pathway, slowing down the growth of cancer cells.
• Are there any serious side effects? Yes, serious side effects can include liver problems and severe skin reactions.
• What should I do if I miss a dose? Do not take the missed dose if it is almost time for your next dose; do not double dose.
• Can I take other medications with Sonidegib? Inform your doctor about all the medications you are taking, as some may interact with Sonidegib.
• How long will I need to take Sonidegib? The duration of treatment will depend on your response and the advice of your healthcare provider.
• Is Sonidegib effective for all types of skin cancer? No, it is indicated only for locally advanced basal cell carcinoma (not metastatic or other skin cancers like squamous cell carcinoma).

Brand Names

Sonidegib is marketed under the brand name Odomzo. It is available as 200 mg capsules (oral formulation).

Conclusion

Sonidegib represents a targeted therapy advancement in the treatment of advanced basal cell carcinoma, offering hope to patients who have limited options. Its targeted mechanism of action, oral administration, and proven efficacy make it a valuable tool in oncology. However, it is essential for patients to discuss their medical history and potential risks with their healthcare provider before starting treatment.